Why the study?
Understanding of how polyclonal neutralizing antibody responses target non-enveloped viruses remains limited.
The study provides a comprehensive analysis of how polyclonal sera target a non-enveloped viral capsid, revealing significant heterogeneity in human responses compared to mice and identifying structural parameters predictive of viral escape.
Answers are grounded in this paper and cite their sources.
Individual variation in picornavirus polyclonal neutralization may complicate vaccine design; leaves open how to target dominant sites in future studies.
Despite their fundamental role in resolving viral infections, our understanding of how polyclonal neutralizing antibody responses target non-enveloped viruses remains limited. To define these responses, we obtained the full antigenic profile of multiple human and mouse polyclonal sera targeting the capsid of a prototypical picornavirus. Our results uncover significant variation in the breadth and strength of neutralization sites targeted by individual human polyclonal responses, which contrasted with homogenous responses observed in experimentally infected mice. We further use these comprehensive antigenic profiles to define key structural and evolutionary parameters that are predictive of escape, assess epitope dominance at the population level, and reveal a need for at least two mutations to achieve significant escape from multiple sera. Overall, our data provide the first comprehensive analysis of how polyclonal sera target a non-enveloped viral capsid and help define both immune dominance and escape at the population level.
No takes yet. Share an insight, caveat, or question.
Álvarez‐Rodríguez et al. (2022) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: